









# ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
 Lassa fever	University of Oxford		IAVI		
 MERS	Uvax	IDT Barinthus/ University of Oxford			
 Nipah		PHV University of Oxford			
 Rift Valley fever	UC Davis Afrigen	Wageningen U.	University of Oxford and KEMRI – Wellcome Trust		
 Chikungunya				IVI/Bharat	Valneva
 COVID-19*					SK Bioscience Moderna Novavax University of Hong Kong Biological E Clover AZ/Oxford
 Broadly protective Betacoronavirus	VIDO IVI consortium Bharat/U Syd/ExcellGene SK Bioscience	Panacea/THSTI CPI/CalTech NEC Intravacc			
 Mpox		BioNTech			

(\*) CEPI has also funded booster studies of SARS-CoV-2 vaccines developed by Medigen and Vaxxinity

	Preclinical		Phase I	Phase II	Phase IIb/III & III	Registration
 Disease X	Akagera	Tiba bio	Lemonex			
	Chungbuk University	Gennova*				
	University of Queensland	Emervax				
	Moderna	HMRI				
	SK bio	Imperial				
	University of Oxford	Amplitude				
	Boost Biopharma	Nagasaki University				
	Centivax	VitriVax				
	ACM Bio	Abera Bioscience				
	POP BIO					
 Broadly protective Filovirus vaccines	Adaptvac					








(\*) Gennova funding supports platform optimisation and development of candidate vaccines against Rabies and Nipah virus.

(‡) Includes Lassa, MERS and Nipah funding




(\*\*) Includes COVID-19 variant and BPBC funding. Project funding complete.

Rift Valley fever, Chikungunya, and some COVID-19 and other projects are supported by European Commission co-funding.

\*\*\* Funding is part of a total investment of up to \$90m.

	DISEASE	DEVELOPER	PHASE	TECHNOLOGY	CEPI FUNDING (IN USD)
	Lassa fever	University of Oxford	Preclinical	Viral Vector	Up to \$19 million‡
		IAVI	Phase 2	Viral Vector	Up to \$64.4 million
	MERS	University of Oxford + Barinthus	Phase I	Viral vector	Up to \$47 million‡
		IDT	Phase I	Viral vector	Up to \$36 million
		Uvax bio	Preclinical	Protein based	Up to \$2.6 million
	Nipah	University of Oxford	Phase I	Viral Vector	Up to \$19 million‡
		PHV	Phase I	Viral vector	Up to \$43.6 million
	Rift Valley fever	UC Davis	Preclinical	Live attenuated	Up to \$40 million
		Wageningen University	Phase I	Live attenuated	Up to \$38.4 million
		University of Oxford and KEMRI-Wellcome Trust	Phase II	Viral Vector	Up to \$3.7 million
		Afrigen	Preclinical	mRNA	Up to \$6.2 million
	Chikungunya	IVI/Bharat	Phase IIb/III	Inactivated virus	Up to \$14.1 million
		Valneva	Registration	Live attenuated	Up to \$65.9 million
	COVID-19	SK Bioscience	Registration	Protein based	Up to \$210 million
		Biological E	Registration	Protein based	Up to \$14 million
		Moderna	Registration	Protein based	Up to \$1 million
		Clover	Registration	Protein based	Up to \$397.4 million
		University of Hong Kong	Registration	Live attenuated	Up to \$5.4 million
		AZ/University of Oxford	Registration	Viral vector	Up to \$384 million
		Novavax	Registration	Protein based	Up to \$399 million
	Mpox	BioNTech	Phase I/II	mRNA	Up to \$72 million***

(##) Includes \$13.38 million for funding a Nipah candidate and \$3.6 for funding for a Rabies candidate/platform optimisation.

	Broadly protective Betacoronavirus	IVI Consortium	Preclinical	mRNA	Up to \$23.9 million
		VIDO	Preclinical	Protein based	Up to \$22 million
		Bharat/ U Sydney/ ExcellGene	Preclinical	Protein based	Up to \$19.9 million
		CPI/Caltech	Preclinical	Protein based	Up to \$30 million
		NEC	Preclinical	RNA	Up to \$4.8 million
		SK Bioscience	Preclinical	Protein based	Up to \$50 million
		Panacea/THSTI	Preclinical	Protein based	Up to \$12.5 million
		Intravacc	Preclinical	Protein based	Up to \$4.8 million
	Disease X	Abera Bioscience	Preclinical	Protein based	Up to \$1.5 million
		Akagera	Preclinical	mRNA	Up to \$1.5 million
		ACM Bio	Preclinical	mRNA	Up to \$2.9 million
		Amplitude	Preclinical	SaRNA	Up to \$1 million
		Boost Biopharma	Preclinical	Protein based	Up to \$5 million
		Centivax	Preclinical	mRNA	Up to \$5.0 million
		Chungbuk National University	Preclinical	SaRNA	Up to \$0.9 million
		Emervax	Preclinical	CircRNA	Up to \$2.2 million
		Gennova	Preclinical	mRNA	Up to \$16.98 million##
		HMRI	Preclinical	CircRNA	Up to \$3.8 million
		Imperial College London	Preclinical	SaRNA	Up to \$8.4 million
		Lemonex	Phase I	mRNA	Up to \$4.9 million
		Moderna	Preclinical	mRNA	Not yet at a stage where CEPI provides funding to Moderna.
		Nagasaki University	Preclinical	mRNA	Up to \$5 million
		University of Oxford	Preclinical	Viral Vector	Up to \$80 million
		POP BIO	Preclinical	Protein based	Up to \$1.5 million
		University of Queensland	Preclinical	Protein based	Up to \$10.6 million
		SK Bioscience	Preclinical	mRNA	Up to \$40 million
		Tiba Bio	Preclinical	mRNA	Up to \$2 million
		VitriVax	Preclinical	Inactivated virus/Protein based	Up to \$5 million
	Broadly protective Filovirus vaccines	AdaptVac	Preclinical	Virus-like particle	Up to \$12.4 million